Acer Therapeutics Inc ACER shares are trading higher by 7.43% to $1.52 after the company and Relief Therapeutics announced the CNIPA issued a utility model patent covering dosage form claims related to ACER-001's polymer-coated formulation.
Acer Therapeutics says, specifically, the newly issued patent covers dosage form claims related to ACER-001's polymer-coated formulation for oral administration as a potential treatment for urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). The newly issued patent has an expiration date of August 24, 2031.
See Also: Why Twitter Stock Is Falling Today
Acer Therapeutics operates as a pharmaceutical company.
According to data from Benzinga Pro, Acer Therapeutics has a 52-week high of $3.77 and a 52-week low of $1.16.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.